These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
259 related items for PubMed ID: 27624168
1. Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE study. Maruhashi T, Higashi Y, Kihara Y, Yamada H, Sata M, Ueda S, Odawara M, Terauchi Y, Dai K, Ohno J, Iida M, Sano H, Tomiyama H, Inoue T, Tanaka A, Murohara T, Node K, PROLOGUE Study Investigators. Cardiovasc Diabetol; 2016 Sep 13; 15(1):134. PubMed ID: 27624168 [Abstract] [Full Text] [Related]
2. Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOGUE study. Tomiyama H, Miwa T, Kan K, Matsuhisa M, Kamiya H, Nanasato M, Kitano T, Sano H, Ohno J, Iida M, Sata M, Yamada H, Maemura K, Tanaka A, Murohara T, Node K. Cardiovasc Diabetol; 2016 Nov 03; 15(1):150. PubMed ID: 27809848 [Abstract] [Full Text] [Related]
3. Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients. Ayaori M, Iwakami N, Uto-Kondo H, Sato H, Sasaki M, Komatsu T, Iizuka M, Takiguchi S, Yakushiji E, Nakaya K, Yogo M, Ogura M, Takase B, Murakami T, Ikewaki K. J Am Heart Assoc; 2013 Jan 28; 2(1):e003277. PubMed ID: 23525426 [Abstract] [Full Text] [Related]
4. Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study. Yamada H, Tanaka A, Kusunose K, Amano R, Matsuhisa M, Daida H, Ito M, Tsutsui H, Nanasato M, Kamiya H, Bando YK, Odawara M, Yoshida H, Murohara T, Sata M, Node K, PROLOGUE Study Investigators. Cardiovasc Diabetol; 2017 May 11; 16(1):63. PubMed ID: 28490337 [Abstract] [Full Text] [Related]
5. Effects of dipeptidyl peptidase-4 inhibitors on cardiac and endothelial function in type 2 diabetes mellitus: A pilot study. Leung M, Leung DY, Wong VW. Diab Vasc Dis Res; 2016 May 11; 13(3):236-43. PubMed ID: 26993495 [Abstract] [Full Text] [Related]
6. A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes. Jax T, Stirban A, Terjung A, Esmaeili H, Berk A, Thiemann S, Chilton R, von Eynatten M, Marx N. Cardiovasc Diabetol; 2017 Jan 21; 16(1):13. PubMed ID: 28109295 [Abstract] [Full Text] [Related]
10. Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: a randomized, placebo-controlled, double-blind trial. Tripolt NJ, Aberer F, Riedl R, Url J, Dimsity G, Meinitzer A, Stojakovic T, Aziz F, Hödl R, Brachtl G, Strunk D, Brodmann M, Hafner F, Sourij H. Cardiovasc Diabetol; 2018 May 17; 17(1):71. PubMed ID: 29773079 [Abstract] [Full Text] [Related]
13. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study. Nakamura K, Oe H, Kihara H, Shimada K, Fukuda S, Watanabe K, Takagi T, Yunoki K, Miyoshi T, Hirata K, Yoshikawa J, Ito H. Cardiovasc Diabetol; 2014 Jul 30; 13():110. PubMed ID: 25074318 [Abstract] [Full Text] [Related]
14. Sitagliptin attenuates the progression of coronary atherosclerosis in patients with coronary disease and type 2 diabetes. Li B, Luo YR, Tian F, Chen YD, Tian JW, Ding Y, Zhu M, Li JW, Zhang YQ, Shi WM. Atherosclerosis; 2020 May 30; 300():10-18. PubMed ID: 32247073 [Abstract] [Full Text] [Related]
15. Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial. Ueda S, Shimabukuro M, Arasaki O, Node K, Nomiyama T, Morimoto T. Cardiovasc Drugs Ther; 2018 Feb 30; 32(1):73-80. PubMed ID: 29435776 [Abstract] [Full Text] [Related]
16. The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes. Kubota Y, Miyamoto M, Takagi G, Ikeda T, Kirinoki-Ichikawa S, Tanaka K, Mizuno K. J Korean Med Sci; 2012 Nov 30; 27(11):1364-70. PubMed ID: 23166419 [Abstract] [Full Text] [Related]
18. GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial. Smits MM, Tonneijck L, Muskiet MH, Hoekstra T, Kramer MH, Diamant M, Serné EH, van Raalte DH. Arterioscler Thromb Vasc Biol; 2016 Oct 30; 36(10):2125-32. PubMed ID: 27562916 [Abstract] [Full Text] [Related]
19. Effects of concomitant drugs on sitagliptin-mediated improvement in glycemic control in Japanese patients with type 2 diabetes. Hirata T, Inukai K, Morimoto J, Katayama S, Ishida H. Prim Care Diabetes; 2014 Oct 30; 8(3):265-70. PubMed ID: 24530100 [Abstract] [Full Text] [Related]
20. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin. Ba J, Han P, Yuan G, Mo Z, Pan C, Wu F, Xu L, Hanson ME, Engel SS, Shankar RR. J Diabetes; 2017 Jul 30; 9(7):667-676. PubMed ID: 27502307 [Abstract] [Full Text] [Related] Page: [Next] [New Search]